As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

As the COVID-19 pandemic clearly demonstrated, health is an integral part of Europe’s security. That principle underpinned a ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

Watch out, Gilead and Novartis: there's a new CAR-T in town ... with 3% grade 3 events and no grade 4 or 5 events. Like other CAR-T products, Aucatzyl still comes with an FDA boxed warning for CRS, ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

EQS-News: APONTIS PHARMA AG / Key word (s): 9 Month figures/Change in Forecast APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ rally witnessed over the past few days following the election results. The ...

The global sore throat lozenges market is projected to be valued at USD 4.4 billion in 2024 and is expected to grow at a CAGR of 5.6%, reaching an estimated value of approximately USD 7.5 billion by ...